2023 - Research.com Microbiology in United Kingdom Leader Award
2022 - Research.com Microbiology in United Kingdom Leader Award
His main research concerns Microbiology, Drug resistance, Antibiotic resistance, Antibacterial agent and Antibiotics. His study in Microbiology is interdisciplinary in nature, drawing from both Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. His research investigates the link between Drug resistance and topics such as Escherichia coli that cross with problems in Plasmid.
He combines subjects such as Vancomycin, Biotechnology, Methicillin-resistant Staphylococcus aureus and Gene with his study of Antibiotic resistance. His Antibacterial agent research integrates issues from Ceftazidime, Citrobacter freundii, Piperacillin and Genetic transfer. His Antibiotics course of study focuses on Infection control and Carbapenemase-Producing Enterobacteriaceae.
David M. Livermore mostly deals with Microbiology, Antibacterial agent, Antibiotics, Drug resistance and Enterobacteriaceae. His Microbiology research is multidisciplinary, incorporating perspectives in Pseudomonas aeruginosa and Klebsiella pneumoniae, Escherichia coli. His research investigates the connection with Antibacterial agent and areas like Ceftazidime which intersect with concerns in Cefotaxime and Piperacillin.
His Antibiotics study combines topics from a wide range of disciplines, such as Internal medicine and Infection control. His Enterobacteriaceae research is multidisciplinary, relying on both Agar dilution, Enterobacter and Bacteria. David M. Livermore has included themes like Tigecycline, Colistin, Carbapenem and Meropenem in his Imipenem study.
David M. Livermore mainly investigates Microbiology, Agar dilution, Pseudomonas aeruginosa, Drug resistance and Avibactam. His Microbiology study incorporates themes from Ceftazidime, Enterobacteriaceae and Acinetobacter baumannii. He has researched Agar dilution in several fields, including Penicillin, Carbapenem, Cephalosporin, Acinetobacter and Klebsiella.
The various areas that David M. Livermore examines in his Pseudomonas aeruginosa study include Colistin, Efflux and Strain. His work deals with themes such as Bacterial genetics and Antibiotics, which intersect with Drug resistance. His Antibiotics research incorporates themes from Internal medicine and Escherichia coli.
His primary areas of investigation include Microbiology, Agar dilution, Klebsiella pneumoniae, Metagenomics and Nanopore sequencing. His Microbiology research is multidisciplinary, incorporating elements of Avibactam, Enterobacteriaceae and Enterobacter. He has researched Enterobacteriaceae in several fields, including Klebsiella and Cefepime.
His Klebsiella pneumoniae research integrates issues from Plasmid, Outbreak, Multilocus sequence typing and Carbapenem. David M. Livermore usually deals with Carbapenem and limits it to topics linked to Infection control and Drug resistance, Antibiotics, Internal medicine, Carbapenemase-Producing Enterobacteriaceae and Pediatrics. David M. Livermore interconnects Gold standard, Polymerase chain reaction and Illumina dye sequencing in the investigation of issues within Metagenomics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy;Mark Alexander Howard Toleman;Timothy Rutland Walsh;Jay Bagaria.
Lancet Infectious Diseases (2010)
beta-Lactamases in laboratory and clinical resistance.
David M. Livermore.
Clinical Microbiology Reviews (1995)
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
David M. Livermore.
Clinical Infectious Diseases (2002)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L Silvia Munoz-Price;L Silvia Munoz-Price;Laurent Poirel;Robert A Bonomo;Robert A Bonomo;Mitchell J Schwaber.
Lancet Infectious Diseases (2013)
Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study
Timothy Rutland Walsh;Timothy Rutland Walsh;Janis Lesley Weeks;David M. Livermore;Mark Alexander Howard Toleman.
Lancet Infectious Diseases (2011)
Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.
Neil Woodford;Matthew J. Ellington;Juliana M. Coelho;Jane F. Turton.
International Journal of Antimicrobial Agents (2006)
CTX-M: changing the face of ESBLs in Europe
David M. Livermore;Rafael Canton;Marek Gniadkowski;Patrice Nordmann.
Journal of Antimicrobial Chemotherapy (2006)
Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance
Neil Woodford;Jane F. Turton;David M. Livermore.
Fems Microbiology Reviews (2011)
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe
R. Cantón;M. Akóva;Y. Carmeli;C.G. Giske.
Clinical Microbiology and Infection (2012)
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii
Jane F. Turton;M. Elaina Ward;Neil Woodford;Mary E. Kaufmann.
Fems Microbiology Letters (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: